Accordingly, a clinical trial found that FLS in the labial glands of some SS patients treated with belimumab for 28 weeks became negative; the B cell/T cell ratio and BAFF-positive cells in the labial salivary gland also decreased (80). The gene discussed is TNFSF13B; the disease is synovial sarcoma.